LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

Kodu・Aktsiate loetelu・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Avatud

SektorTervishoid

22.78 0.53

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

22.45

Max

23.24

Põhinäitajad
By Trading Economics
Sissetulek	675K 53M
Müük	1.8M 148M
P/E Sektori keskmine	12.608 105.69
Kasumimarginaal	35.57
Töötajad	181
EBITDA	-3.1M 76M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+49.25% upside

Turustatistika
By TradingEconomics
Turukapital	26M 2.6B
Eelmine avamishind	22.25
Eelmine sulgemishind	22.78

Uudiste sentiment

By Acuity

26%

74%

77 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

N/A / 24.28 Toetus ja vastupanu

Catalyst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. nov 2025, 21:34 UTC

Tulu

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13. nov 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13. nov 2025, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13. nov 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q EPS 52c >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q Sales $22.6B >JBS

13. nov 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13. nov 2025, 22:02 UTC

Tulu

Nu Holdings 3Q Net $783M >NU

13. nov 2025, 22:01 UTC

Tulu

Nu Holdings 3Q Rev $4.2B >NU

13. nov 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13. nov 2025, 21:50 UTC

Tulu

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13. nov 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13. nov 2025, 21:41 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13. nov 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13. nov 2025, 21:33 UTC

Tulu

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13. nov 2025, 21:31 UTC

Tulu

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q EPS 34c >FIGR

13. nov 2025, 21:23 UTC

Tulu

Intchains Group 3Q Rev $1.3M >ICG

13. nov 2025, 21:03 UTC

Tulu

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13. nov 2025, 21:02 UTC

Tulu

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Rev $6.8B >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Gross Margin 48.0% >AMAT

Võrdlus sarnastega

Hinnamuutus

Catalyst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

49.25% tõus

12 kuu keskmine prognoos

Keskmine 34 USD 49.25%

Kõrge 35 USD

Madal 33 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Catalyst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Catalyst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 24.28Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

77 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.